Chirurgia del Fegato a Firenze!

Dal 1° Marzo 2023, Chirurgia del Fegato sarà all'Università di Firenze
AOUC Azienda Ospedaliero-Universitaria Careggi - Largo Brambilla, 3 - 50134 Firenze

Resezione vs. Sorafenib nell’epatocarcinoma

I risultati di questo studio combinato dei due gruppi ITA.LI.CA e HE.RC.O.LE.S mostrano che la resezione epatica offre migliori risultati in termini di sopravvivenza dei pazienti portatori di epatocarcinoma intraepatico non metastatico avanzato rispetto alla terapia medica con il sorafenib. Quindi, in accordo con un approccio personalizzato alla terapia di questa malattia e seguendo una strategia terapeutica gerarchica, il trattamento chirurgico con la resezione epatica, se realizzabile sia dal punto di vista clinico che dal punto di vista tecnico, dovrebbe essere proposto come terapia di prima linea.
Simone Famularo, Matteo Donadon, Federica Cipriani, Felice Giuliante, Silvia Ferri, Ciro Celsa, Alessandro Ferrero, Francesco Giuseppe Foschi, Gian Luca Baiocchi, Elisabetta Biasini, Claudia Campani, Raffaele Dalla Valle, Filippo Pellizzaro, Gianluca Svegliati Baroni, Giovanni Raimondo, Andrea Mega, Marco Chiarelli, Marcello Maestri, Antonio Gasbarrini, Elio Jovine, Gian Luca Grazi, Gian Ludovico Rapaccini, Andrea Ruzzenente, Filomena Morisco, Rodolfo Sacco, Riccardo Memeo, Michele Crespi, Adelmo Antonucci, Davide P. Bernasconi, Fabrizio Romano, Guido Griseri, Luca Aldrighetti, Guido Torzilli, Franco Trevisani: Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison. In: Annals of Surgery, vol. 275, no. 4, pp. 743 – 752, 2022, ISSN: 00034932, (Cited by: 0).

Abstract

Objective:The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario.Background data:The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial.Methods:BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups.Results:Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P < 0.001). Similar trends were observed after subgrouping patients by ECOG-PS = 0 and ECOG-PS >0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007).Conclusions:In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib. © 2022 Lippincott Williams and Wilkins. All rights reserved.

manda un messaggio a https://t.me/@ChirurgiaFegato

Invia subito una richiesta con Telegram

Apri direttamente Telegram ed inviaci un SMS veloce e sicuro: riceverai una risposta alla tua necessità in tempi brevissimi

Chirurgia del Fegato all'Università di Firenze!

Chirurgia Epato-Bilio-Pancreatica

AOUC Azienda Ospedaliero-Universitaria Careggi
Largo Brambilla, 3 – 50134 Firenze

Manda una mail a: info@chirurgiadelfegato.it

oppure

Invia un messaggio con Telegram